Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for reversal of neuromuscular blockade in pediatric patients younger than 2 years
NL-OMON49696Phase 4Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex in neuromuscular block (NMB) (5 arms), sponsored by Merck & Co. Primary endpoints: Pharmacokinetic parameters, Time to neuromuscular recovery and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on NL-OMON49696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49696.